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development of atherosclerosis and vascular disorders associ-
ated with CKD (Satoh 2012; Shang et al 2017). 
One of the mediators of endothelial dysfunction in patients with 
CKD is inflammation (Bernelot Moens et al 2017; Lilitkarntakul 
et al 2014). However, associations between inflammation, en-
dothelial dysfunction and formation of cardiovascular compli-
cations have been insufficiently highlighted in pediatric patients 
with pre- dialysis CKD. In this work, we studied the correla-
tion between inflammation, endothelial dysfunction and left 
ventricular hypertrophy in children with CKD stage 2 and 3.
Materials and methods
Patients, groups 
We study 47 children (24 boys, 23 girls) aged from 6 to 17 years 
with chronic pyelonephritis (CP) and CKD 2 and 3 stages, who 
were subjected to inpatient treatment at the department of neph-
rology of “Dnipropetrovsk Regional Children’s Clinical Hospital” 
DRC. The control group consisted of 20 healthy children. The 
Іntroduction
Chronic kidney disease (CKD) remains an important medical and 
social health problem, given the high prevalence and increased 
risk of mortality and morbidity (Rhee et al 2015). In patients with 
CKD, cardiovascular pathology is the most important cause of 
increased mortality and it directly affects the long-term survival 
(Fox et al 2012; Mahmoodi et al 2012). Similarly to adults, in 
paediatric patients with chronic renal failure, the association of 
cardiovascular diseases most often result in death (Mitsnefes 
et al 2013; Weaver et al 2017). In patients with CKD, cardio-
vascular complications are associated with traditional risk fac-
tors, such as left ventricular hypertrophy (LVH) (Matsushita et 
al 2017), as well as nontraditional risks such as anemia, calci-
fication, hyperhomocysteinemia, vitamin D deficiency, insulin 
resistance and oxidative stress (He et al 2017; Mann et al 2015; 
Matsushita et al 2016; Matsushita et al 2014). There are studies 
that prove the decisive role of endothelial dysfunction in the 
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planned clinical trial was approved by the Bioethics Committee 
of the Dnipropetrovsk Medical Academy MOH of Ukraine and 
was carried out in compliance with the Helsinki Declaration 
guidelines (1975). All participants and / or their parents were 
fully informed about the methods and scope of the study and 
provided their written informed consent to participate.
Criteria for the patients inclusion into the study were as fol-
lows: the presence of voluntary informed consent of the child 
and her parents to participate in the clinical study; patients age 
from 6 to 17 years 11 months 29 days; the presence of a veri-
fied chronic pyelonephritis and CKD 2 and 3stages diagnosis; 
the absence of clinical and laboratory signs of chronic pyelone-
phritis exacerbation. Criteria for the patients exclusion from the 
study were: refusal of the child or his/her parents to participate 
in the clinical trial; the presence of congenital heart disease or 
other primary cardiac diseases, acute infections. 
All patients underwent routine medical history taking, physi-
cal examination, ultrasound imaging and laboratory assess-
ment. The examination was carried out during the remission 
period of chronic pyelonephritis, at least one month after the 
last exacerbation. The biochemical parameters (level of urea, 
creatinine, uric acid, electrolytes, albumin) necessary for de-
termining the renal function status were determined. The ve-
locity of glomerular filtration was calculated using the formula 
by Schwartz et al. Definition and classification of CKD stages 
were made using standard criteria (Stevens et al 2013). The 
level of C-reactive protein (CRP) was studied by means of the 
latex agglutination method using the “Granum” set of reagents 
(Ukraine). Microalbuminuria was determined by means of the 
“Micral-Test”, Roche Diagnostics (Switzerland).
Ultrasound investigation
The ultrasound examination was carried out in a specially de-
signed room (purpose-built room), where the air temperature is 
permanently maintained at 22-24oC. The test was carried out in 
the morning after 12-h overnight fasting. At least 12 hours be-
fore the study, patients avoided taking coffee and tea, perform-
ing physical exercises. 48 hours before the study all vasoactive 
medicines were discontinued. Patients were examined in a lying 
position after a 10-15 minute rest.
Endothelial function was evaluated by using digital ultrasonic 
diagnostic complex “Toshiba Xario (Japаn)” using a 7.5 MHz 
sensor. We performed an ultrasound assessment of endotelium-
dependent flow-mediated dilation (FMD) of the brachial artery 
and calculated the percentage of the increase in the diameter of 
brachial artery. The norm was an increase in FMD more than 
10% (Celermajer 1998). 
Echocardiography (EchoCG) to determine the presence of 
left ventricular (LV) hypertrophy (LVH) was carried out with 
“Acuson CV70” ultrasound scanner (Siemens) in 2D mode us-
ing the standard procedure. The main indices of systolic and 
diastolic function of the LV were determined, including end-
diastolic index (EDI), end-systolic index (ESI), ejection frac-
tion (EF), left ventricular relative wall thickness (LVRWT). The 
calculation of the LV myocardial mass 
(LVM) and the myocardial mass index (LVMI) were performed. 
The LVM was calculated using the formula by Devereux and 
Reichek (Devereux 1977). The Z-scores of LVM were calcu-
lated according to the height (Foster et al 2008). The LVMI 
was obtained by dividing the LVMI by the height (mass [g] 
/ height [m] 2.7) (de Simone et al 1992). for the normalizing 
and linearizing the correlation between LVM and the height. 
Lipid hypertrophy was determined when the LVMI was ≥ 95 
percentiles for healthy children and adolescents (Khoury et al 
2009). Since the LVMI that is indexed to the height does not 
completely take into account the changes due to growth, we 
also used Z-scores based on age and sex (Khoury et al 2009). 
Measurement of office blood pressure (OBP) was performed 
before the ultrasound examination after the patient’s sitting for 
10-15 minutes in a calm condition.
Statistical analysis 
Statistical analysis was carried out using STATISTICA software 
for Windows version 8.0 (StatSoft, Tulsa, OK). Distribution of 
variables was tested with Shapiro-Wilk’s test. Non-parametric 
variables are given as median (interquartile range) and per-
centage for categorical variables. The Kruskal–Wallis One 
Way Analysis of Variance (ANOVA) on Ranks (H) was used 
for testing a statistically significant difference in the median 
values among all groups. Significance point was defined using 
Bonferonni adjustment. To compare two independent samples 
non-parametric Mann-Whitney U-test was applied. The corre-
lation between variables was assessed by Spearman correlation 
coefficient. The level of significance was set at 0.05.
Results
About 80.9% (38/47) of patients with chronic pyelonephritis 
had of organic urodynamics disorders (congenital anomalies 
of the kidneys and / or urinary tract), 19.1% (9/47) - functional 
urodynamics disorders (neurogenic dysfunction of the bladder).
Patients were divided into groups depending on the stage of 
chronic kidney disease: the 1-st group included 30 patients 
with CKD stage 2 (GFR 60 to 90 ml/min/1.73m2), the 2nd 
group - 17 patients with CKD stage 3 (GFR from 30 to 59 ml/
min/1.73m2). Among the 47 patients examined, 37 were treat-
ed with angiotensin-converting enzyme (ACE) inhibitors, i.e. 
80.0% (24/30) of patients with CKD stage 2 and 76.5% (13/17) 
- with CKD stage 3.
The main clinical data and indices are presented in table 1.
There were no differences in age and gender among the groups 
under study. Patients in group 2 (CKD stage 3) had significantly 
lower height rates (p = 0.024), body weight (p = 0.031), hemo-
globin (p = 0.012), and statistically higher levels compared to 
the control group children of systolic (p = 0.025) and diastolic 
blood pressure (p = 0.026), uric acid (p = 0.019) (table 1) com-
pared with the control group. In patients with CKD in both 
groups, levels of CRP (p = 0.038 and p = 0.009, respectively) 
and microalbuminuria (p = 0.001 and p = 0.0001, respectively) 
were reliably higher than those in the control group.
The comparative characteristics of the echocardiographic exam-
ination results are presented in table 2. In children with CKD, 
during the disease progression, the left ventricular cavity is en-
larged, which is confirmed by the reliable increase of ESI (p = 
0.011) and EDI (p = 0.016) in patients with CKD stage 3 com-
pared to that in the control group. The LVMI was reliably higher 
compared to that in the control group both in patients with CKD 
stage 2 (p = 0.025) and in those with CKD stage 3 (p = 0.007).
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FMD index was reliably lower in patients of group 1 and 2 
(H=42.7, p= 0.0000; p1-2=0.013; pcontrols-1=0.033; pcontrols-2=0.0000) 
compared to that in the control group (table 3). Endothelial dys-
function was detected in 90% of patients with CKD stage 2 and 
in 100% of those with CKD stage 3.
A significant negative correlation between levels of FMD and 
LVMI (r=-0.49, p=0.031), CRP (r=-0.76, р<0.001), microalbu-
minuria (r=-0.65, р<0.001) was found in all patients with CKD.
Table 1. Main clinical data and indices in the examined patients
Indices, units of measure
Groups of examined patients
Group 1
 (n=30)
Group 2
 (n=17)
Control group
(n=20)
Gender, m/f 14/16 10/7 9/11
Age, years 11.28(6.46;16.72) 11.08(7.80;15.86) 10.78(6.98;16.16)
Height (Z-score) -0.09(-1.05;0.70) -0.88(-2.16;-0.33)с 0.44(-0.16;1.24)#
Body weight (Z-score) -0.95(-1.67;0.47) -0.98(-1.59;0.01)с 0.12(-0.27;0.72)#
BMI (Z-score) 0.27(-0.35;0.66) -0.97(-1.71;0.35) -0.04(-0.11;0.39)
Hemoglobin, g/l 122(113;129) 105(92;112)с 125(119;130)#
Systolic BP, mm Hg 116(112;126) 122 (118;131)с 114 (108;121)#
Diastolic BP, mm Hg 73(65;82) 83(77;87)с 68(62;78)#
GFR, ml/min 72.0(66.7;82.0)c# 40.6(36.8;51.8)c* 100.6(95.8;124.2)*#
Blood serum uric acid, mmol/l 0.33(0.27;0.39) 0.45(0.38;0.61)c* 0.24(0.22;0.34)#
CRP, mg/ml 4.07 (3.27;7.11)c# 7.28 (6.99;11.08)c* 1.03 (0.06;1.88)a*#
Microalbuminuria, mg/ml 19.6 (14.3;47.2)c# 84.2 (42.7;287.6)c* 3.5 (2.7;15.1)*#
Note. *- - the probable difference when compared with the indicators of group 1;  # - the probable difference when compared with 
the indicators of group 2; с – the probable difference when compared with the indicators of the control group; a –CRP level was 
determined in 17 children in the control group.
Indices, units of measure
Groups of examined patients
Group 1
(n=30)
Group 2
 (n=17)
Control group
(n=20)
EDI, мл/м2 57.9 (53.5; 66.2) 62.9(59,9; 71,6)c 53.6(47.8; 60.0)#
ESI, мл/м2 10.9(14.5; 22.6) 22.1(19.5; 26.3)c 20.5(15.0; 23.2)#
EF, % 63.9(60.9; 69.2) 63.4(63.1; 69.2) 66.6(65.2; 73.7)
LVMI (г/м2,7) 31.7(28.0; 39.2) 34.2(30.7; 44.1)c 30.8(26.2; 34.6)#*
LVMI (Z-score) 1.69(1.04; 2.67)c 2.42(1.79; 3.09)c* 0.37(-0.17; 1.07)*#
LVRWT 0.36(0.25; 0.51) 0.36(0.33; 0.39) 0.34(0.32; 0.41)
LVH (%) 36.70% 47.00% -
Table 2. Main morphological parameters of the left ventricle in the examined children, (Me (Q25; Q75))
Note. *- the probable difference when compared with the indicators of group 1; # - the probable difference when compared with 
the indicators of group 2; с – the probable difference when compared with the indicators of the control group.
Indices, units of measure
Groups of examined patients
Group 1
 (n=30)
Group 2
 (n=17)
Control group
(n=20)
FMD, % 9.7 (6.3; 13.7)c# 5.9 (3.2; 8.9)*c 17.6 (11.6; 25.2)*#
FMD ≤10%, % (n) 90.0 (27) 100.0 (17) 5.0 (1)
Note. *- the probable difference when compared with the indicators of group 1; # - the probable difference when compared with 
the indicators of group 2; с – the probable difference when compared with the indicators of the control group.
Table 3. Dynamics of the brachial artery diameter during the endothelium dependent vasodilation test in the examined patients
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Discussion
Іn previous studies іt has been determined that patients with 
CKD have endothelial dysfunction, which aggravates the risk 
of cardiovascular complications (Satoh 2012).  Endothelial dys-
function along with inflammation, microalbuminuria plays an 
important role as a nonconventional risk factor for cardiovas-
cular events in CKD. LVH is one of the major traditional risk 
factors for cardiovascular complications in the pediatric popu-
lation of patients with CKD.
However, the mechanisms underlying the association between 
these factors are completely unclear, particularly in children 
with mild-to-moderate renal function decrease.
In the present study, it was found that children with CKD stages 
2 or 3 had signs of systemic inflammation, endothelial dysfunc-
tion and left ventricular hypertrophy. This information is con-
sistent with previous studies performed among adult patients 
(Yilmaz et al 2011). The results indicate that the levels of sys-
temic inflammation (at CRP H = 35.2, p = 0.001) and endothelial 
dysfunction (at the level of FMD H = 42.7, p = 0.0000) grow 
with the renal function decreasing, that is, during the progres-
sion of CKD.
At present, fundamental studies confirm that inflammation can 
lead to the endothelial cells damage (Yilmaz et al 2011; D’Apolito 
et al 2015) and, conversely, that the endothelium synthesizes 
various inflammatory molecules (Carrero et al 2009). Recent 
data suggest that inflammation, oxidative stress and endothelial 
dysfunction in patients with CKD have a synergistical effect. 
The data of these studies are confirmed in our work by the pres-
ence of a strong correlation between levels of CRP and FMD.
Our study also demonstrated the link between endothelial dys-
function and left ventricular hypertrophy in pediatric patients 
with CKD and mild-to-moderate renal dysfunction. Despite 
the fact that LVH is common in patients with CKD, first of 
all, its development is associated with inflammation and oxi-
dative stress. However, until now, the mechanisms underlying 
the development of LVH in pediatric CKD patients are still not 
clearly defined.
We assume that it can be endothelial dysfunction that plays a 
decisive role in the remodeling of the left ventricle in the co-
hort of patients we studied. In detail, the effect of endothelial 
dysfunction on the LVH development was studied on the hy-
pertension model. It has been proven that endothelin, as a pow-
erful microvascular constrictor and pro-inflammatory agent, is 
released from the damaged endothelium and promotes the de-
velopment of heart hypertrophy. However, we can not extrapo-
late this mechanism to our study, because among children with 
CKD stages 2-3, a very small number of patients had hyper-
tension, and besides, we have not obtained a reliable associa-
tion with LVMI.
Elucidation of association between endothelial dysfunction and 
hypertension in hypersympathicotonia should be considered as 
a promising direction for further studies on the mechanisms of 
cardiovascular events in patients with CKD at the initial stages.
Conclusion
Children with chronic pyelonephritis have early signs of en-
dothelial dysfunction and systemic inflammation, which wors-
ens during mild-to-moderate CKD progression. The presence 
of the reliable correlations between endothelial dysfunction, 
systemic inflammation and LVMI suggests the involvement of 
the endothelium in the development and maintenance of chronic 
inflammation and the left ventricular hypertrophy formation.
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